<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twelve patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> were treated with <z:chebi fb="0" ids="2636">amifostine</z:chebi> plus recombinant human erythropoietin (rHuEpo) for 6 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%) </plain></SENT>
<SENT sid="2" pm="."><plain>Two of 8 patients with a platelet count &lt; 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count &lt; 1.5 x 10(9)/L </plain></SENT>
<SENT sid="3" pm="."><plain>Compared to rHuEpo or <z:chebi fb="0" ids="2636">amifostine</z:chebi> used as single agents, their combination did not offer substantial advantages </plain></SENT>
</text></document>